Perioperative Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Muscle-Invasive Bladder Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study
Lancet Oncol 2023 Dec 21;[EPub Ahead of Print], C Pfister, G Gravis, A Flechon, C Chevreau, H Mahammedi, B Laguerre, A Guillot, F Joly, M Soulie, Y Allory, V Harter, S CulineFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.